Early drug study aims to understand BI 1839100's journey in the body
NCT ID NCT06572111
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial in 8 healthy men aims to understand how the experimental drug BI 1839100 is processed by the body. Part A tracks the drug and its radioactive label in urine and feces after an oral dose. Part B compares how much of the drug reaches the bloodstream when given orally versus intravenously. The study is terminated, so results may be limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 1839100
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICON-Groningen-62040
Groningen, 9728 NZ, Netherlands